NewAmsterdam Pharma COO Douglas Kling resigns, effective Aug. 14

Reuters2026/07/22 20:12

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NewAmsterdam Pharma said Chief Operating Officer Douglas Kling will resign effective Aug. 14, 2026.
Kling is leaving to become chief executive officer of another clinical-stage biotech company.
A separation agreement is expected.
An advisor agreement is also expected for transition support on the PREVAIL trial of obicetrapib and other programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-312390), on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NewAmsterdam Pharma COO Douglas Kling resigns, effective Aug. 14

You may also like

Crypto prices